Allopregnanolone as regenerative therapeutic for alzheimer's: phase 2 clinical trial

Active Project Grant Awarded Last action

Award ID
R01AG063826
Recipient
Awarding agency
Obligated
$79,930,932

Award facts

Assistance listing
93.866 Aging Research
Completion date 93% complete
Originally
Funding
  • $72,560,117.00 Federal
  • $7,370,815.00 Non-federal
Place of performance
Tucson, AZ 85721, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $6,580,973 $0
Amendment $6,580,973 $0
Amendment $6,580,973 $0
Amendment $0 $0
Amendment $7,279,977 $0
Amendment $7,279,977 $0
Amendment $7,552,351 $0
Amendment $7,552,351 $0
Amendment $7,370,815 $0
Amendment $7,370,815 $7,370,815
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Original award $8,410,912 $0
Show all 17

Subawards

Subrecipient Amount Awarded
University Of Southern California Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial $72,885
ADM Diagnostics, Inc. $769,363
Syneos Health LLC $13,900,892

Quick answers

Who received award R01AG063826?

R01AG063826 was awarded to University Of Arizona by National Institute on Aging (National Institutes of Health) on August 15, 2019.

How much is award R01AG063826 worth?

$79,930,932 has been obligated on R01AG063826: $72,560,117 in federal funding and $7,370,815 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award